Nuvation Bio (NUVB) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nuvation Bio (NUVB) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 32.8% versus a loss of 11.1%. Over five years, STOK leads with a +3.3% price change compared with -49.1% for NUVB. Nuvation Bio is the larger company by market cap ($1.72 billion vs $1.55 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NUVB | STOK |
|---|---|---|
| Share price | $4.91 | $23.98 |
| Market cap | $1.72B | $1.55B |
| 1-day change | +1.03% | -1.28% |
| YTD return | -45.76% | -23.47% |
| 1-year return | +32.79% | -11.06% |
| 5-year return | -49.11% | +3.27% |
| EPS (TTM) | $-0.44 | $-3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.75 | $40.22 |
| 52-week low | $3.36 | $20.32 |
| Distance from 52-week high | -49.64% | -40.38% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +164.77% | +93.74% |
| Average volume | 5.65M | 852.03K |
| Shares outstanding | 350.12M | 64.53M |
| Employees | 305 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NUVB has outperformed STOK by 43.8 percentage points over the past year.
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 305 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
NUVB vs STOK FAQ
Which is bigger, Nuvation Bio or Stoke Therapeutics?
Nuvation Bio (NUVB) is larger, with a market capitalization of $1.72B compared with $1.55B for Stoke Therapeutics (STOK).
Which stock has performed better over the past year, NUVB or STOK?
NUVB returned +32.79% over the past 12 months, compared with -11.06% for STOK (price return, excluding dividends). Past performance does not predict future results.
Are Nuvation Bio and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.